

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM684597

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	RELEASE OF SECURITY INTEREST		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
MACQUARIE US TRADING LLC		11/25/2019	Limited Liability Company: DELAWARE
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	KADMON CORPORATION, LLC		
<b>Street Address:</b>	450 EAST 29th STREET		
<b>City:</b>	NEW YORK		
<b>State/Country:</b>	NEW YORK		
<b>Postal Code:</b>	10016		
<b>Entity Type:</b>	Limited Liability Company: DELAWARE		
<b>PROPERTY NUMBERS Total: 5</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Registration Number:</b>	2952736	RIBASPHERE	
<b>Registration Number:</b>	2887092	RIBASPHERE	
<b>Registration Number:</b>	3248539	RIBAPAK	
<b>Registration Number:</b>	4296020	KADMON	
<b>Registration Number:</b>	4296019	KADMON	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	2156562498		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	215-656-3381		
<b>Email:</b>	pto.phil@dlapiper.com		
<b>Correspondent Name:</b>	IP GROUP OF DLA PIPER LLP (US)		
<b>Address Line 1:</b>	ONE LIBERTY PLACE		
<b>Address Line 2:</b>	1650 MARKET ST. SUITE 5000		
<b>Address Line 4:</b>	PHILADELPHIA, PENNSYLVANIA 19103		
<b>NAME OF SUBMITTER:</b>	WILLIAM L. BARTOW		
<b>SIGNATURE:</b>	/williamlbartow/		
<b>DATE SIGNED:</b>	10/28/2021		
<b>Total Attachments: 13</b>			

CH \$140.00 2952736

source=Kadmon\_Macquarie - IP Security Release#page1.tif  
source=Kadmon\_Macquarie - IP Security Release#page2.tif  
source=Kadmon\_Macquarie - IP Security Release#page3.tif  
source=Kadmon\_Macquarie - IP Security Release#page4.tif  
source=Kadmon\_Macquarie - IP Security Release#page5.tif  
source=Kadmon\_Macquarie - IP Security Release#page6.tif  
source=Kadmon\_Macquarie - IP Security Release#page7.tif  
source=Kadmon\_Macquarie - IP Security Release#page8.tif  
source=Kadmon\_Macquarie - IP Security Release#page9.tif  
source=Kadmon\_Macquarie - IP Security Release#page10.tif  
source=Kadmon\_Macquarie - IP Security Release#page11.tif  
source=Kadmon\_Macquarie - IP Security Release#page12.tif  
source=Kadmon\_Macquarie - IP Security Release#page13.tif

## Termination and Release of Patent and Trademark Security Interest

This **Termination and Release of Patent and Trademark Security Interest** (the "**Release**"), effective *nunc pro tunc* as of November 25, 2019 (the "**Effective Date**"), is made by MACQUARIE US TRADING LLC (the "**Administrative Agent**") in favor of KADMON CORPORATION, LLC, a Delaware limited liability company (the "**Grantor**"). Grantor and Administrative Agent are sometimes referred herein as each a "**Party**" and, collectively, the "**Parties**."

**WHEREAS**, pursuant to the terms of (i) that certain Intercreditor Agreement, dated as of August 18, 2015, between Grantor and Administrative Agent, among others (as amended, restated, modified or supplemented from time to time, the "**Intercreditor Agreement**"), (ii) that certain Security Agreement, dated as of August 28, 2015, between Grantor and Administrative Agent, among others (as amended, restated, modified or supplemented from time to time, the "**Security Agreement**"), (iii) that certain Patent and Trademark Security Agreement, dated as of August 25, 2015, between Grantor and Administrative Agent (as amended, restated, modified or supplemented from time to time, the "**Patent and Trademark Security Agreement**"), (iv) those certain Amended and Restated Patent Security Agreement and Amended and Restated Trademark Security Agreement, each dated as of November 16, 2014, between Grantor and Administrative Agent (as amended, restated, modified or supplemented from time to time, the "**Existing Security Agreements**," and collectively with the Intercreditor Agreement, Security Agreement and Patent and Trademark Security Agreement, the "**Intercreditor and Security Agreements**"), the Grantor granted to Administrative Agent a security interest in and to all of Grantor's right, title and interest in and to certain collateral described below in Section 2(a) and (b).

**WHEREAS**, the Patent and Trademark Security Agreement was recorded with the United States Patent and Trademark Office on September 8, 2015, at patent assignment Reel 036573, Frame 0001.

**WHEREAS**, the IP Security Agreement was recorded with the United States Patent and Trademark Office on September 2, 2015, at trademark assignment Reel 5615, Frame 0624.

**WHEREAS**, Grantor has satisfied in full the terms of the Intercreditor and Security Agreements and requests a release of the Released IP Collateral (as defined below), and, effective as of the Effective Date, Administrative Agent wishes to fully terminate, discharge and release its lien and security interest in the Released IP Collateral.

**NOW, THEREFORE**, for good and valuable consideration, the receipt, adequacy and legal sufficiency of which are hereby acknowledged by the Parties, Administrative Agent hereby agrees for the benefit of Grantor, as follows:

1. **Defined Terms.** Unless otherwise defined herein, capitalized terms defined in the Intercreditor and Security Agreements, have the meaning given to them in the applicable Intercreditor and Security Agreement.

2. **Release of Security Interest.** Effective *nunc pro tunc* as of the Effective Date, the Administrative Agent agrees to fully terminate, release and discharge, and hereby does fully

terminate, release, and discharge, its lien and security interest in all of each Grantor's present and future right, title and interest in and to the following:



- a. all patents and patent applications, in each case whether now owned by Grantor or hereafter acquired and whether now existing or hereafter coming into existence, including without limitation those listed on Schedule A hereto, and all related patents and applications thereto, including all reissuances, continuations, continuations-in-part, revisions, extensions, re-examinations thereof, any patents and patent applications claiming priority to said patents and patent applications or from which said patents and patent applications claim priority, and pending applications associated therewith; and
  - b. all of the trademarks, whether now owned or at any time hereafter acquired, of Grantor that are registered with, or for which applications for registration have been filed with, the United States Patent and Trademark Office, including the trademarks listed on Schedule B hereto, and all registrations and pending applications associated therewith (collectively with (a), the "Released IP Collateral").
3. Further Assurances. Administrative Agent hereby authorizes the applicable Grantor to (i) record this Release with the USPTO, (ii) file UCC financing statement amendments with the applicable filing office in order to memorialize the release of the security interest of the Administrative Agent in the Released IP Collateral, and/or (iii) otherwise record or file this Release in the applicable foreign or domestic governmental office or agency. Administrative Agent hereby further agrees to duly execute, acknowledge, procure and deliver any further documents and to do such other acts, in each case at Grantor's expense, as may be reasonably necessary to effect the release of the security interest in the Released IP Collateral contemplated hereby.
4. Counterparts. This Release may be executed in any number of counterparts and by the different Parties hereto in separate counterparts, each of which when so executed shall be deemed to be an original, and all of which taken together shall constitute one and the same agreement. Delivery of an executed counterpart of a signature page to this Release electronically or by telecopy shall be as effective as delivery of a manually executed counterpart of this Release.
5. Successors and Assigns. This Release will be binding on and shall inure to the benefit of the Parties hereto and their respective permitted successors and assigns.
6. Severability. Each provision of this Release will be interpreted in such a manner as to be effective and valid under applicable law, but if any term or other provision of this Release is held to be invalid, illegal or unenforceable under applicable law, all other provisions of this Release shall remain in full force and effect.

*[Remainder of page intentionally left blank]*

IN WITNESS WHEREOF, the Parties have caused this Release to be duly executed by its authorized representatives as of the Effective Date.


ADMINISTRATIVE AGENT:

MACQUARIE US TRADING LLC

By:    
Name: Joshua Karlin Anita Chiu  
Title: Authorized Signatories

GRANTOR:

KADMON CORPORATION, LLC

By:   
Name: Gregory Moss  
Title: EVP, General Counsel

[Signature Page to Release]

Schedules A and B

*See attached*

Schedule A  
to Patent and Trademark Security Agreement

## PATENTS AND PATENT APPLICATIONS

## Kadmon Corporation, LLC

Matter	Country	Application No	Title	Status
473WO1	P.C.T.	PCT/US14/59572	RHO KINASE INHIBITORS (KL148 SERIES)	PENDING
474WO1	P.C.T.	PCT/US15/11657	IMMUNOMODULATORY AGENTS	PENDING
486P1	United States	62/185223	GLUCOSE UPTAKE INHIBITORS	PENDING
487P1	United States	62/185231	TREATMENT OF INFECTIOUS DISEASES WITH GLUCOSE UPTAKE INHIBITORS	PENDING
470US1	US [PCT]	14/431936	RHO KINASE INHIBITORS	PENDING
472US1	US [PCT]	14/431954	HUMAN ANTI-VEGFR-2/KDR ANTIBODIES	PENDING
472WO1	P.C.T.	PCT/US13/63754	HUMAN ANTI-VEGFR-2/KDR ANTIBODIES	PENDING
471US1	US [PCT]	14/431948	TREATMENT OF OCULAR DISORDERS	PENDING
475WO1	P.C.T.	PCT/US15/19658	TREATMENT OF BRAIN AND CENTRAL NERVOUS SYSTEM TUMORS	PENDING
476WO1	P.C.T.	PCT/US15/25176	TREATMENT OF GVHD	PENDING
477P1	United	62/061097	HUMAN ANTI-VEGFR-2/KDR	PENDING

110703275 v3

PATENT  
REEL: 036573 FRAME: 0007

	States		ANTIBODIES	
467US2	United States	14/801335	METHODS FOR TREATMENT OF BREAST CANCER NONRESPONSIVE TO TRASTUZUMAB	PENDING
485P1	United States	62/113132	ANTI-PD1 ANTIBODIES	PENDING
462P1	United States	62/111522	STABLE TRIENTINE FORMULATIONS	PENDING

A. Kadmon Corporation, LLC has acquired exclusive rights in and to certain Patents and patent applications related to the compound XL647 pursuant to an Amended and Restated License Agreement, dated as of September 6, 2011, between Kadmon Corporation, LLC and Symphony Evolution, Inc. Such Patents and patent applications include:

Country	Title	Status	Application No.	Patent No.
USA	Receptor-Type Kinase Modulators and Methods of Use	Granted	10/522004	7576074
USA	Receptor-Type Kinase Modulators and Methods of Use	Granted	12/455867	8658654
USA	Receptor-Type Kinase Modulators and Methods of Use	Pending	14/060123	

Country	Title	Status	Application No.	Patent No.
USA	Use Of A Receptor-Type Kinase Modulator For Treating Polycystic Kidney Disease	Pending	13/818844	

B. Kadmon Corporation, LLC has acquired exclusive rights in and to certain Patents and patent applications related to the botanical compound PHY906 pursuant to a License Agreement, dated as of February 4, 2011, between Kadmon Corporation, LLC and Yale University. Such Patents and patent applications include:

110703275 v3

PATENT  
REEL: 036573 FRAME: 0008



Matter	Country Desc	Application No	Grant No	Title	Status Desc
462US2	US [PCT]	10/220876	7025993	HERBAL COMPOSITION PHY-906 AND ITD USE IN CHEMOTHERAPY	GRANTED
463US1	United States	11/100433	7534455	HERBAL COMPOSITION PHY906 AND ITS USE IN CHEMOTHERAPY	GRANTED
465US1	US [PCT]	12/997513	8871279 B2	USE OF THE COMBINATION OF PHY906 AND A TYROSINE KINASE INHIBITOR AS A CANCER TREATMENT REGIMEN	GRANTED
466US2	United States	14/605180		USE OF PHY906 AS TREATMENT FOR INFLAMMATORT BOWEL DISEASE AND/OR IRRITABLE BOWEL SYNDROME	PENDING
464US3	United States	14/581610		HERBAL- COMPOSITION	PENDING

PATENT  
 REEL: 036573 FRAME: 0009

110703275 v3

				PHY906 AND ITS USE IN CHEMOTHERAPY	
464US1	US [PCT]	12/527302	8309141 B2	HERBAL- COMPOSITION PHY906 AND ITS USE IN CHEMOTHERAPY	GRANTED

C. Kadmon Corporation, LLC has acquired exclusive rights in and to certain Patents and patent applications pursuant to that certain Exclusive License Agreement, dated as of December 8, 2010, between Kadmon Corporation, LLC and Princeton University. Such Patents and patent applications include:

Matter	Country Desc	Application No	Grant No	Title	Status Desc
46102	US [PCT]	13/579967		INHIBITORS OF LONG AND VERY LONG CHAIN FATTY ACID METABOLISM AS BROAD SPECTRUM ANTI-VIRALS	ALLOWED
464US1	US [PCT]	13/982331		INHIBITORS OF MTOR KINASE AS ANTI-VIRAL AGENTS	PENDING
46276	P.C.T.	PCT/US10/43101		INHIBITORS OF CELL-CODED MTOR KINASE WITH ANTI-VIRAL ACTIVITY	PENDING
46202	US [PCT]	13/386547		INHIBITORS OF MTOR KINASE AS ANTI-VIRAL AGENTS	PENDING
46003	United States	12/156517	8158677 B2	TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS	GRANTED
46004	United States	13/438616	9029413 B2	TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS	GRANTED
46005	United States	14/709756		TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC	PENDING

110703275 v3

PATENT  
REEL: 036573 FRAME: 0010

				PATHWAYS	
--	--	--	--	----------	--

D. Kadmon Corporation, LLC has acquired exclusive rights in and to certain Patents and patent applications pursuant to that certain Sub-License Agreement, dated as of April 8, 2011, among NT Life Sciences, LLC, Kadmon Corporation, LLC, and Surface Logix, Inc. Such Patents and patent applications include:

Family	Country	Application No.	Grant No.	Title	Status
217US2	United States	13/715644	8916576 B2	PHARMACOKINETICALLY IMPROVED COMPOUNDS	GRANTED
217US3	United States	14/581746		PHARMACOKINETICALLY IMPROVED COMPOUNDS	PENDING
217US	US [PCT]	11/887218	8357693 B2	PHARMACOKINETICALLY IMPROVED COMPOUNDS	GRANTED
218US2	United States	13/708420	8853394	PHARMACOKINETICALLY IMPROVED COMPOUNDS	GRANTED
230US	US [PCT]	13/255879		RHO KINASE INHIBITORS	PENDING

Case	Status	App Number	Country Name	Pat Number	Title
69587/	Granted	11/407,500	USA	8980915	INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND APO-B SECRETION
69587/CON	Pending	14/660,453	USA		INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER

110703275 v3

PATENT  
REEL: 036573 FRAME: 0011

					PROTEIN AND APO-B SECRETION
--	--	--	--	--	-----------------------------

E. Kadmon Corporation, LLC has acquired exclusive rights in and to certain Patents and patent applications related to MMP-14 antibodies pursuant to that certain License Agreement, dated as of September 16, 2012, between Kadmon Corporation, LLC and Dyax Corp. Such Patents and patent applications include:

Docket No.	Country	Application No.	Patent No.	Status	Title
K2043-708710	US	11/648423	7745587	Granted	ANTIBODIES THAT BIND MMP-14
K2043-708720	US	12/776195	8106168	Granted	METALLOPROTEINASE BINDING PROTEINS
K2043-708721	US	13/335185	9051377	Granted	METHOD FOR TREATING BREAST CANCER USING ANTIBODY BINDING TO MMP-14
K2043-710210	US	12/337218	8183008	Granted	EVALUATING MMP EXPRESSION IN PATIENT STRATIFICATION AND OTHER THERAPEUTIC, DIAGNOSTIC AND PROGNOSTIC METHODS FOR CANCER
K2043-710610	US	12/337140	8147836	Granted	COMPOSITIONS AND METHODS FOR TREATING OSTEOLYTIC DISORDERS COMPRISING MMP-14 BINDING PROTEINS
K2043-710640	US	13/338622	8501181	Granted	COMPOSITIONS AND METHODS FOR TREATING OSTEOLYTIC DISORDERS COMPRISING MMP-14 BINDING PROTEINS
K2043-7141US	US	14/353212		Pending	COMBINATION THERAPY COMPRISING AN MMP-14 BINDING PROTEIN

110703275 v3

PATENT REEL: 036573 FRAME: 0012

F. Kadmon Corporation, LLC has acquired exclusive rights in and to certain Patents and patent applications related to salirasinib pursuant to that certain Asset Purchase Agreement, dated as of December 16, 2011, between Kadmon Corporation, LLC and Concordia Pharmaceuticals, Inc. Such Patents and patent applications include:


Country	Appl. / Patent	Title	Status
United States	5,705,528 (RE39682)	FARNESYL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM	Granted
United States	6,462,086	NON-MALIGNANT DISEASE TREATMENT WITH RAS ANTAGONISTS	Granted
United States	6,946,485	TREATMENT OF POST-ANGIOPLASTY RESTENOSIS AND ATHEROSCLEROSIS WITH RAS ANTAGONISTS	Granted
United States	8,232,253	TREATMENT OF LUNG CANCER	Granted
United States	8,338,481	ALKOXYALKYL S-PRENYLTHIOSALICYLATES FOR TREATMENT OF CANCER	Granted
United States	13/521,637	TREATMENT OF MULTIPLE SCLEROSIS	Filed
Canada	2577310	METHODS AND COMPOSITIONS FOR ORAL DELIVERY OF FTS	Granted
United States	8,088,756	METHODS AND COMPOSITIONS FOR ORAL DELIVERY OF FTS	Granted
United States	14/662420	METHODS AND COMPOSITIONS FOR ORAL DELIVERY OF FTS	Pending

110703275 v3

PATENT REEL: 036573 FRAME: 0013


Schedule B  
to Patent and Trademark Security Agreement

TRADEMARKS AND TRADEMARK APPLICATIONS

Record	Mark/Script/App/Reg. No.	Start/Key Dates	Goods/Services	Owner
US Federal	RIBASPHERE and Design  SN:76-535804 RN:2,952,736	Registered: May 17, 2005  Class 5 First Use: April 7, 2004 Filed: July 29, 2003	<b>Class 5:</b> Pharmaceutical preparations for use, through prescription, in the treatment of chronic hepatitis c	Kadmon Corporation, LLC
US Federal	RIBASPHERE SN:76-412404 RN:2,887,092	Registered: September 21, 2004  Class 5 First Use: April 7, 2004 Filed: May 24, 2002	<b>Class 5:</b> Pharmaceutical preparations for use, through prescription, in the treatment of chronic hepatitis c	Kadmon Corporation, LLC
US Federal	RIBAPAK SN:78-721241 RN:3,248,539	Registered: May 29, 2007  Class 5 First Use: September 29, 2006	<b>Class 5:</b> Pharmaceutical preparation for the treatment of hepatitis c	Kadmon Corporation, LLC

110703275 v3

PATENT  
REEL: 036573 FRAME: 0014

Record	Mark/Serial/APP/Reg. No.	Status/Key Dates	Goods/Services	Owner
		Filed: September 27, 2005		
US Federal	KADMON and Design  SN:85-148670 RN:4,296,020	Registered February 26, 2013  Class 5 First Use: August 28, 2012 Filed: October 8, 2010	<b>Class 5:</b> Pharmaceuticals for use in the fields of oncology, immunology and viruses	Kadmon Corporation, LLC
US Federal	KADMON  SN:85-148651 RN:4,296,019	Registered February 26, 2013  Class 5 First Use: August 28, 2012 Filed: October 8, 2010	<b>Class 5:</b> Pharmaceuticals for use in the fields of oncology, immunology and viruses	Kadmon Corporation, LLC

110703275 v3

PATENT  
REEL: 036573 FRAME: 0015

RECORDED: 09/08/2015